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Abstract 
Objectives: To investigate the cost-effectiveness of adalimumab in combination with 
methotrexate, compared with methotrexate alone, for the management of uveitis 
associated with Juvenile Idiopathic Arthritis (JIA-U). 
Design: A cost-utility analysis based on a clinical trial and decision analytic model. 
Participants: Children and adolescents aged 2 to 18 years with persistently active JIA-U, 
despite optimized methotrexate treatment for at least 12 weeks. 
Methods: The SYCAMORE trial [ISRCTN10065623] of methotrexate (up to 25mg per week) 
with or without fortnightly administered adalimumab (20mg or 40mg, according to body 
weight) provided data on resource use (based on patient self-report and electronic records) 
and health utilities (from the Health Utilities Index questionnaire). Surgical event rates and 
long-term outcomes were based on data from a 10-year longitudinal cohort. A Markov 
model was used to extrapolate the effects of treatment based on visual impairment. 
Main outcome measures: Medical costs to the National Health Service in the UK, utility of 
defined health states, quality-adjusted life years (QALY), and incremental cost per QALY. 
Results: Adalimumab in combination with methotrexate resulted in additional costs of 
£39,316 with a 0.30 QALY gain compared with methotrexate alone, resulting in an 
incremental cost-effectiveness ratio of £129,025 per QALY gained. The probability of cost-
effectiveness at a threshold of £30,000 per QALY was less than 1%. Based on a threshold 
analysis, a price reduction of 84% would be necessary for adalimumab to be cost-effective. 
Conclusions: Adalimumab is clinically effective in JIA-U, however its cost-effectiveness is not 
demonstrated compared with methotrexate alone in the UK setting. 
 
Keywords: Anti-TNF, Juvenile Idiopathic Arthritis, uveitis, cost-effectiveness, economic 
evaluation 
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Introduction 
Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children, with a 
prevalence of 1-2 per 1,000 children in the UK. Between 12-38% of patients develop 
inflammation of the uvea (uveitis) which is associated with cataracts, glaucoma and macular 
oedema1,2. Treatment approaches to JIA-associated uveitis (JIA-U) include corticosteroids 
administered topically (first-line) and systemically (severe or sight-threatening JIA-U), and 
methotrexate (preferred second-line DMARD)3. However, 15-50% of children will develop 
refractory uveitis,4–6 requiring further intervention. The efficacy of the anti-tumour necrosis 
factor α (TNF-α) monoclonal antibody, adalimumab, in JIA is well established,7 and its use is 
recommended for children with active arthritis who have not responded adequately to 
DMARD8. The SYCAMORE trial (ISRCTN10065623) demonstrated the clinical effectiveness of 
adalimumab in combination with methotrexate for the treatment of JIA-U, with a hazard 
ratio of 0.25 (95% confidence interval, CI 0.12, 0.49; p <0.0001) compared with 
methotrexate alone9.  
Adalimumab remains on patent and costs around £350 per 40mg dose, administered 
fortnightly,10 but a biosimilar will be marketed from October 2018. For its licensed indication 
in JIA, adalimumab was judged by the National Institute for Health and Care Excellence 
(NICE) to be cost-effective, with an incremental cost-effectiveness ratio (ICER) of £30,000 
per quality-adjusted life year (QALY) gained8. There are no published economic evaluations 
in JIA-U; however a recent analysis of adalimumab and dexamethasone for treating active 
uveitis in adults showed that adalimumab was not cost-effective at £94,523 per QALY 
gained,11 though these findings may not be generalizable to children with JIA-U. 
Within the National Health Service (NHS) in England, the availability of adalimumab for the 
management of paediatric chronic non-infectious anterior uveitis is via an interim clinical 
commissioning policy12. It is also recommended for use within NHS Wales13 but currently 
not in NHS Scotland14. We aimed to inform the cost-effective use of adalimumab for JIA-U in 
the NHS by conducting a model-based economic evaluation incorporating evidence from the 
SYCAMORE trial. 
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Methods 
SYCAMORE trial data 
SYCAMORE was a multicentre, double-blind, randomized, placebo-controlled trial to assess 
the clinical effectiveness of adalimumab in refractory uveitis associated with JIA9,15. The trial 
recruited children and adolescents aged 2 to 18 years with active JIA-associated uveitis, 
despite stable methotrexate treatment for at least 12 weeks, from 14 UK centres. Ninety 
participants aged between 2 and 18 years who were taking methotrexate without 
improvement in their uveitis were randomised in a 2:1 ratio to receive fortnightly 
subcutaneous injections of adalimumab (20mg for participants <30kg; 40mg for participants 
≥30 kg) or placebo in a double-blind phase until treatment failure, or until 18-months had 
lapsed. They were then treated at their clinician’s discretion, which could include 
adalimumab, and followed up for a further 6 months. Recruitment into the SYCAMORE trial 
was terminated early following an interim analysis which demonstrated a significantly lower 
risk of treatment failure in the adalimumab group9. All participants in the placebo group 
stopped the trial regimen and were followed up for 6 months as per protocol. All 
participants receiving adalimumab continued in an open-label follow-up in accordance with 
trial protocol. 
Economics evaluation overview 
The primary outcome of the economic evaluation was the incremental cost per QALY gained 
with adalimumab combined with methotrexate, versus methotrexate alone. In order to 
avoid time horizon bias, the primary analysis required a comparison of the long-term costs 
and consequences of adalimumab in JIA-U. A purposive search of the literature did not 
identify any relevant study to inform this extrapolation. We therefore used data from a 
longitudinal cohort of patients with idiopathic and JIA-U attending the Bristol Regional 
Tertiary Pediatric Uveitis clinic (the ‘Bristol cohort’16). The economic analysis adopted the 
perspective of the NHS in the UK, and is reported according to the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS)17. 
Data sources 
Health utilities 
Utility was measured using an interviewer-administered and proxy-assessed version of the 
Health Utilities Index questionnaire,18 administered at baseline and subsequently at 3, 6, 9, 
12, 18 months and end of follow-up. Responses to the questionnaire were mapped onto the 
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HUI Mark 3 (HUI3) classification system which has validity in children19. It also includes 
vision among its health domains, along with hearing, speech, ambulation, dexterity, 
emotion, cognition and pain. Preference-based scoring algorithms were used to convert the 
descriptive health classifications into values for each health dimension, and a multi-attribute 
model was used to derive a utility score18. Although the EuroQol EQ-5D is the preferred 
generic, preference-based utility measure in the UK20, it lacks validity in children21 and is less 
sensitive to changes in vision22.  
Resource use 
The use of trial and concomitant medicines was recorded by physicians at each study visit in 
dedicated sections of the trial case report form, and supplemented by patient diary records. 
Hospital admission and adverse event data were obtained from hospital electronic patient-
level information costing systems or patient administration systems and were 
supplemented by baseline and 3-monthly resource use questionnaires. These 
questionnaires were completed by research nurses based on patient interviews and entries 
made in patient diaries, and included participants’ use of hospital (outpatient clinic, hospital 
and A&E admissions), primary (e.g. GP consultations) and community (e.g. school nurse) 
care. Further details on the data collection methods are available from 
http://www.dirum.org/instruments/details/82.  
Unit costs 
All resource use was valued in monetary terms using appropriate UK unit costs estimated at 
the time of analysis (cost year 2016). The unit costs of medicines were obtained from 
standard NHS sources10,23 (Table 1). Participants’ use of hospital services were costed 
according to healthcare resource group (HRG) codes, using unit costs from the National 
Tariff 2016-1724  or the National Schedule of Reference Costs 2015-1625. Unit costs for 
primary and community care services were sourced from the Personal Social Services 
Research Unit 201526. The cost of surgery was assumed as the mean cost for paediatric 
ophthalmology, outpatient procedures25.  
Visual acuity 
Data on the long-term consequences of using biologics in clinical practice could only be 
matched to trial outcomes by visual acuity. This was based on LogMAR scores in the worst 
eye, which was considered most clinically relevant, with a score <0.3 indicative of no visual 
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impairment, and ≥0.3 indicating a degree of visual impairment. Trial participants had their 
LogMAR scores recorded at every visit, including unscheduled visits.   
Long-term outcomes and surgery 
The Bristol cohort of 91 children with JIA-U16, collected between 1997 and 2014, provided 
10-year data on LogMAR scores, which were recorded at diagnosis, and at 1, 3, 5 and 10 
years of follow-up, and the number and nature of surgeries performed. Some overlap 
existed between SYCAMORE and cohort patients, with the Bristol recruiting centre 
contributing 28 of 90 trial participants, of which 15 were included in the longitudinal 
dataset. 
 
Analysis 
Economic model 
A trial-based analysis was conducted with an 18-month time horizon, corresponding with 
data from the double-blind phase of SYCAMORE, where available, and supplemented by 
post-trial treatment open-label and follow-up data, as necessary. A Markov model was 
constructed in Microsoft® Excel® 2013 to extrapolate the analysis by 10-years beyond the 
initial 18-month period of the trial-based analysis. A simulated cohort of patients entered a 
Markov model which consisted of three health states defined by visual impairment and 
survival (Figure 1). Patients were initially distributed according to the proportion of time 
spent in each state, by trial arm, over the preceding 18 months. The Bristol cohort was used 
to estimate the probabilities associated with transitions among health states, either with or 
without eye surgery (Table 2). A standardized mortality ratio of 3.9 (95%CI 0.8, 11.3) was 
applied to account for mortality27,28. The model had a cycle length of 1 year, and a half-cycle 
correction was applied.  
Censored data 
Any censoring of data on utility and time in visual impairment health state were imputed 
using the predictive mean matching approach29.  Ten imputed datasets were created from a 
set of imputation models constructed from a range of potential prognostic factors (trial arm, 
age, gender, baseline visual impairment) and outcome variables (cost and exposure to 
adalimumab during the post-trial treatment open-label and follow-up phases). 
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Early trial closure cross-over 
Intention-to-treat analyses may result in biased estimates of the causal treatment effect if 
participants are non-compliant to the treatment allocated. To account for cross-over effects 
resulting from early trial closure, we therefore applied an instrumental variable (IV) 
regression method with total costs and QALYs as outcome variables, adjusted for age and 
gender30. This method links the average causal effect for compliers to the average intention-
to- treat effects.  For the 10-year modelled extrapolation, costs and QALYs specific to each 
health state were calculated by applying the IV regression, and adjusting for treatment and 
time in state. All regression analyses were performed using STATA 13. 
Key assumptions 
Simulated patients were assumed to be fully adherent to adalimumab which, based on 
expert clinical opinion, was considered to continue for 3-years beyond the initial 18-month 
trial period. Progression of visual impairment after 18-months was assumed to be at the 
same rate for patients on either adalimumab or placebo. 
Base-case analysis 
Total costs were calculated for the 18-month trial-based analysis with an adjustment made 
to apportion drug costs if a medication administration spanned the period preceding 
randomisation, or extended beyond the 18-month time horizon.  QALYs were calculated as 
the area under each patient’s utility-time profile, based on the trapezium rule. The base-
case analysis was defined as pertaining to a 7-year old girl, representative of the median 
demographics of SYCAMORE, and based on the 18-month trial period plus the 10-year 
modelled extrapolation, using the imputed data set to account for missing data, and 
adjusting for the cross-over of trial participants from the placebo arm. Costs and QALYs 
accruing in the model beyond the first year were discounted at an annual rate of 3.5%20. 
Uncertainty analyses 
Parameter uncertainty in trial-based estimates of total costs and QALYs was assessed using 
10,000 bootstrapped replications, and presented as 95% central ranges. Sensitivity analyses 
were conducted to assess the impact of varying: (i) the proportion of patients continuing 
adalimumab after end of study; (ii) the duration of post-study access to adalimumab; (iii) 
patient adherence to adalimumab and methotrexate; (iv) the time horizon of analysis; (v) 
the unit price of adalimumab; (vi) visual impairment rates, using the most and least 
favourable combinations; and (vii) the discount rate of future costs and benefits. Bivariate 
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sensitivity analysis were performed to assess the impact of varying the cost of adalimumab 
with either (i) the disutility associated with visual impairment or (ii) the proportion of 
adalimumab patients who develop visual impairment.  
A probabilistic sensitivity analysis of the base-case analysis was performed using Monte 
Carlo simulation with 10,000 replications. All input parameters were sampled 
simultaneously within their distributions and Cholesky decomposition was used to generate 
probability distributions for regression-based analyses (Table 2). The joint uncertainty in 
costs and QALYs was assessed by considering the probability of adalimumab being cost-
effective with reference to the NICE threshold range of £20,000 to £30,000 per QALY20.  
Patient and public involvement 
The study was supported by a patient advisory group which were involved in the trial from 
the initial prioritisation, design stage and funding applications. They provided detailed input 
into all aspects of the trial protocol design and all subsequent amendments, patient 
information sheets, patient letters, consent forms and the content of the study website. 
Ethical approval 
The SYCAMORE trial was approved by the NHS National Research Ethics Service Committee 
(Hampstead, London) 11/LO/0425, and written, informed consent was given by a parent or 
guardian of each trial participant. 
Results  
Trial-based analysis 
Utilities and QALYs 
Baseline utility scores were 0.83 (95%CI 0.76, 0.89) and 0.87 (95%CI 0.78, 0.96) for the 
adalimumab and placebo groups, respectively. Based on a complete case analysis of 25 
(42%) participants randomised to adalimumab and 3 (10%) participants randomised to 
placebo, the number of QALYs over the 18-month trial period was 1.40 (95% central range, 
CR 1.35, 1.45) and 1.45 (95%CR 1.41, 1.50), respectively. After imputation, the mean QALY 
scores were numerically higher for adalimumab at 1.35, (95%CI 1.30, 1.41) compared with 
the placebo group, at 1.28 (95%CI 1.15, 1.41). 
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Resource use and costs 
Eighteen-month resource use data were available for all trial participants. The total costs 
over the 3-months preceding randomisation were £1,614 (95%CR 1,312, 1,946) and £1,526 
(95%CR 1,072, 2,047) for the adalimumab and placebo groups, respectively (Table 3). During 
the 18-month trial-based analysis, total costs were £15,980 (95%CR 14,213, 17,943) and 
£6,248 (95%CR 3,922, 8,889) respectively, with the majority of the difference in costs 
(£8,579; 88%) attributable to the use of adalimumab. The cost of concomitant medications, 
GP and optician visits differed between groups, but were not major cost drivers, accounting 
for 3%, 0.4% and 0.2% of the difference in total costs, respectively.  
Visual outcomes 
Seven (11.7%) participants randomised to adalimumab, and 2 (6.7%) participants 
randomised to placebo had visual impairment at baseline. At 18-months, complete data 
were available for 43 and 9 participants in each group, respectively, of which 1 (2.3%) and 0 
(0.0%) reported visual impairment. On average, adalimumab participants spent 3.4% (95%CI 
0.5, 6.3) of their time in the visual impairment state compared with 2.1% (95%CI -2.8, 7.0) 
on placebo. Following imputation, participants randomised to adalimumab spent 5.3% 
(95%CI 2.2, 8.4) of time in visual impairment during the 18-month analysis, compared with 
11.2% of time (95%CI 5.6, 16.7) for those randomised to placebo.  
Bristol longitudinal cohort 
The characteristics of patients included in the Bristol cohort are presented in Table 4. Thirty-
seven surgeries in 25 patients were recorded, corresponding to 7.87 per 100 patient-years 
of follow-up. 
Base-case results 
In the base-case analysis, adalimumab in combination with methotrexate generated more 
QALYs but at a higher cost than methotrexate alone. The total costs for each group were 
£70,719 and £31,403, with corresponding QALYs of 8.60 and 8.29, respectively. The 
incremental costs and QALYs were £39,316 and 0.30, resulting in an ICER of £129,025 per 
QALY gained. 
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Sensitivity analyses 
Univariate sensitivity analyses 
The ICER was comparatively stable to a range of sensitivity analyses concerning parameter 
uncertainty and modelling assumptions (Table 5). Alternative assumptions relating to the 
duration and proportion of patients being prescribed adalimumab beyond 18-months, as 
well as adherence to treatment, all resulted in ICERs of at least £115,708 per QALY gained. 
The ICER was stable to varying the distribution of patients across visual impairment states 
on entry to the Markov model. Taking the lower 95%CI for the proportion from the 
adalimumab arm of the trial, and upper 95%CI for the placebo arm, the ICER remained in 
excess of £127,000 per QALY gained. A shortened time horizon of analysis increased the 
ICER to £136,751 per QALY gained. Plausible alternative rates of visual impairment had no 
demonstrable impact on the ICER. However under the extreme condition of all placebo 
group patients transitioning to the state of being visually impaired for the duration of the 
model, the ICER reduced to £78,524 per QALY gained; and in a scenario where, in addition 
to this, all adalimumab patients transition to (and remain) in the state of no visual 
impairment, the ICER reduced further to £53,072 per QALY gained. The ICER also decreased 
with a discounted price of adalimumab, reflecting the future prospect of a biosimilar, but a 
price reduction of 84% would be necessary for adalimumab to be cost-effective at the 
£30,000 per QALY thresholds, respectively. An alternative analytical approach which did not 
account for cross-over resulted in an ICER of £158,259 per QALY gained.  
Two-way sensitivity analyses 
These support our finding that the ICER is sensitive to the cost of adalimumab, but not to 
either the disutility associated with VI or the proportion of adalimumab patients who 
develop VI (Table 5). 
Probabilistic Sensitivity Analyses 
Results from the probabilistic sensitivity analysis indicated that adalimumab is very unlikely 
to be cost-effective, with less than 1% of simulations falling below the £30,000 per QALY 
threshold. These results are illustrated as cost-effectiveness planes in Figure 2. Whilst these 
are presented for 10,000 iterations, the ICER was stable by 2,500 iterations. 
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Discussion 
Principal findings 
This analysis suggests that adalimumab in combination with methotrexate for JIA-U is 
associated with appreciably higher healthcare costs than methotrexate alone, and exceeds 
the threshold for cost-effectiveness operated by the NHS in the UK, by a significant margin. 
The results are robust to changes in parameter estimates and some alternative modelling 
assumptions (although we had limited scope for assessing structural uncertainty), and are 
consistent with the cost-effectiveness of adalimumab used in the management of active 
uveitis in adults11.  
Comparison with other studies 
There are important differences when making comparisons with existing economic 
evaluations of biologic treatments for JIA30. Our estimated incremental QALY gain (0.30 over 
the time horizon of the analysis), for instance, is considerably less than 2.0 QALYs (over a 30 
year period) reported by Shepherd et al.30. While their analysis was also based on HUI3 
utilities, these were derived from a 27-month cohort study of etanercept-treated patients 
whose measured utility at baseline (0.53) was assigned as the annual health-state utility of 
patients treated with methotrexate, and at 15-months (0.74) was assigned to adalimumab-
treated patients. This difference was maintained for the duration of the analysis, and 
treatment continued for much longer than our assumed 4½ years. 
Strengths and limitations of study 
Our analysis had strengths in being based on least biased data (having controlled for cross-
over effects), and estimating cost-effectiveness up until adulthood, but there were also 
many limitations. Principally was the incomplete data on health utilities (QALYs could only 
be calculated for 28 (31%) trial participants) and visual acuity which required a strong 
assumption of data being missing at random. Visual acuity data were censored in 70% and 
28% of patients randomised to placebo and adalimumab, respectively. This was because 
some entered the trial late (in relation to the date of early trial closure) and resulted in 
incomplete follow up. However, adalimumab remained non-cost-effective in a sensitivity 
analysis in which all placebo and no adalimumab patients had visual impairment.  
We were also reliant on a secondary outcome (visual impairment) for matching to the 
external dataset. SYCAMORE was not powered to detect differences in visual impairment, 
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and while the effect of adalimumab on the time to treatment failure (primary endpoint) was 
profound, there was no significant improvement in visual acuity, with a treatment effect on 
worst-eye LogMAR of -0.02 (95% CI -0.07, 0.02)9. 
The extrapolated model also had limitations. There was no consideration of severe visual 
impairment (LogMAR ≥1) or blindness, which is associated with high lifetime costs, and 
significant impacts on quality of life, education and employment. While modelling based on 
the association between anterior chamber (AC) cell count and blindness might have offered 
an alternative approach, this would not have reduced the need for considerable 
assumptions relating to magnitude of long term treatment benefits. In mitigation, expected 
rates of blindness may be low as trial participants had mild or moderate uveitis, with 91% 
having AC cell counts of 1+ or 2+ at baseline9. 
A further limitation was our reliance on data from the Bristol cohort, which included 
patients that may not be comparable to, or managed differently from those recruited to the 
SYCAMORE trial, such as in respect of DMARD treatment or thresholds for prescribing 
biologics16. Moreover, the care offered at Bristol may not be representative of wider 
practice across the NHS. Bristol pioneered combined (ophthalmology and rheumatology) 
clinics from 2006 (70% of the cohort had a diagnosis since 2006), representing the best 
model for service delivery in UK, and were early adopters of biologics for this indication. This 
became a key factor in SYCAMORE, where combined services needed to be developed 
during the trial in many centres, or optimised in others. The Bristol data were limited in 
patient numbers and lack of collection of some important long-term outcome data (e.g. 
disutilities associated with surgery), which may otherwise have added to our interpretation 
of progression of uveitis within the model. Transition probabilities were also independent of 
treatment received since in the Bristol dataset, it appeared that adalimumab was only 
prescribed to those patients in a worse health state, and this would bias the results.  
Notwithstanding these limitations, our analysis was robust to multiple assumptions. In order 
to demonstrate cost-effectiveness, patients receiving adalimumab would need to gain 1.00 
additional QALY over the 10-year time frame, which is unlikely given the QALY gain over the 
course of the trial was only 0.11. Significant price reductions through the introduction of 
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biosimilars would be expected to reduce the ICER, but there would need to be a discount of 
84% to meet the £30,000 per QALY threshold. 
Conclusions and policy implications 
In conclusion, and based on the first and only randomised double-blind, placebo-controlled 
trial in JIA-U, adalimumab is unlikely, at present, to represent a cost-effective treatment 
option in the UK. Our findings have important implications for the routine availability of 
adalimumab for this indication across the NHS in the UK. 
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Table 1. Unit costs of trial medications, outpatient attendances, inpatient attendances 
(including day case and surgical procedures) 
HRG code Health care resource Unit 
cost 
Reference 
Trial medications   
 Adalimumab Humira 40mg or 80mg pre-filled syringe £352.14 [10] 
 Methotrexate Metoject Pen (different volumes)  £14.85 - 
£18.48 
[23] 
 Methotrexate Tablet 2.5mg £0.06 [23] 
 Methotrexate Oral Solution 2mg/ml sugar-free £2.65 [23] 
Outpatient procedures   
BZ22Z Intermediate Vitreous Retinal Procedures £142 [24] 
BZ23Z Minor Vitreous Retinal Procedures £109 [24] 
WF01B Ophthalmology First Attendance - Single Professional £113 [24] 
WF02B Ophthalmology First Attendance – Multi Professional £125 [24] 
WF01A Ophthalmology Follow Up Attendance - Single Professional £64  [24] 
WF02A  Ophthalmology Follow Up Attendance- Multi Professional  £94 [24] 
WF01B Paediatric Ophthalmology First Attendance - Single 
Professional 
£136 [24] 
WF01A Paediatric Ophthalmology Follow Up Attendance - Single 
Professional 
£82 [24] 
 Paediatric Rheumatology attendance £203 [25] 
WF01A Rheumatology Follow Up Attendance - Single Professional £103 [24] 
WF01B Rheumatology First Attendance - Single Professional £225 [24] 
WF02B Rheumatology First Attendance - Multi Professional £246 [24] 
WF02A Rheumatology Follow Up Attendance- Multi Professional £165 [24] 
WF01B Paediatrics First Attendance - Single Professional £222 [24] 
WF01A Paediatrics Follow Up Attendance - Single Professional £135  [24] 
WF02A Paediatrics Follow Up Attendance- Multi Professional £156 [24] 
 Physiotherapy attendance £48 [25] 
Day case    
 Rheumatology £246  [24] 
    
HB29Z Minimal Knee Procedures for Non-Trauma, with length of stay 
≤1 day 
£356 [24] 
PA64A Non-Surgical Ophthalmology with length of stay 0 days £552 [24] 
PH34D Paediatric, Musculoskeletal or Connective Tissue Disorders, 
with CC Score 0 
£590 [25] 
HB39Z Minimal Foot Procedures for Non-Trauma, with length of stay 
≤1 day 
£672 [24] 
PA34B Musculoskeletal or Connective Tissue Disorders, without CC £688 [24] 
PH34C Paediatric, Musculoskeletal or Connective Tissue Disorders, 
with CC Score 1-2 
£696 [25] 
PA34A Musculoskeletal or Connective Tissue Disorders, with CC £988 [24] 
Surgeries    
BZ32B Intermediate, Cataract or Lens Procedures, with CC Score 0-1  £208 [25] 
BZ85Z Very Major or Major, Vitreous Retinal Procedures, ≤18 years £334 [25] 
BZ94B Intermediate, Glaucoma or Iris Procedures, with CC Score 0 £401 [25] 
BZ33Z Minor, Cataract or Lens Procedures £140 [25] 
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BZ93B Major, Glaucoma or Iris Procedures, with CC Score 0-1 £106 [25] 
CC – complication or co-morbidity 
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Table 2. Parameter estimates for the modelled extrapolation 
Parameter Point 
estimate 
Distribution Source 
18-month data (trial-based) 
Cost coefficient: Adalimumab 14,374.01 
Cholesky decomposition Trial data  
Cost coefficient: Age -257.72 
Cost coefficient: Gender -445.89 
Cost coefficient: Constant 3,765.78 
QALY coefficient: Adalimumab 0.11 
Cholesky decomposition Trial data  
QALY coefficient: Age -0.00 
QALY coefficient: Gender -0.02 
QALY coefficient: Constant 1.26 
Month 19-138 (Markov model): Base case model assumptions 
Costs 
Cost coefficient: Adalimumab arm (excluding trial drug costs) 1,437.13 
Cholesky decomposition Trial data Cost coefficient: Time in visual impairment 2,662.57 
Cost coefficient: Constant 1,603.05 
Drug cost: Adalimumab £7,411.73 Gamma~(8.11, 1,370.33) Trial data 
Drug cost: Methotrexate £1,598.17 Gamma~(0.56, 4,315.70) Trial data 
Surgery cost (per surgery transition) £418.71 Gamma~(2.66,157.27) [16] 
Discount rate: Cost (per annum) 0.035 None (fixed) [20] 
QALYs 
QALY coefficient: Adalimumab arm 0.07 
Cholesky decomposition Trial data QALY coefficient: Time in visual impairment -0.00 
QALY coefficient: Constant 0.83 
Discount rate: QALY (per annum) 0.035 None (fixed) [20] 
Probabilities 
Proportion VI: Adalimumab arm 0.05 Beta~(4.75, 85.25) Trial data 
Proportion VI: Placebo arm 0.11 Beta~(10.04, 79.96) Trial data 
No VI -> no VI (no surgery) 0.95 Dirichlet~(162, 4, 14, 2) approximated by 
standardised series of gamma distributions 
[16] 
No VI -> no VI (surgery) 0.01 
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No VI -> VI (no surgery) 0.04 
No VI -> VI (surgery) 0.01 
VI -> no VI (no surgery) 0.33 
Dirichlet~(29, 6, 38, 13) approximated by 
standardised series of gamma distributions 
[16] 
VI -> no VI (surgery) 0.06 
VI -> VI (no surgery) 0.47 
VI -> VI (surgery) 0.14 
Mortality rate* (per annum) 0.000071 None (fixed) [28]  
Standardised mortality ratio 3.9 Lognormal~(3.9,2.6785) [27] 
VI – visual impairment 
*Age based, figure indicated is for 8-year old. 
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Table 3. Disaggregated healthcare resource use and costs, from randomisation to 18-months, by intervention group 
Item of resource use 
Adalimumab  
mean count (95%CR) 
Placebo 
mean count (95%CR) 
Difference in means 
(95% CR) 
GP visits 2.1 (1.4, 2.7) 1.1 (0.5, 1.7) 1.0 (0.1, 1.8) 
Nurse visits 1.2 (0.6, 1.9) 0.4 (0.3, 1.2) 0.7 (-0.2, 1.6) 
Physiotherapist 0.5 (0.2, 0.8) 0.4 (0, 0.8) 0.1 ( 0.4, 0.6) 
Psychologist 0.1 (0.0, 0.2) 0.2 (0.0, 0.5)  -0.1 (-0.4, 0.1) 
OP - HRG - WF01A 2.6 (1.6, 3.8) 1.9 (0.7, 3.3) 0.7 (-1.0, 2.4) 
OP - HRG - WF01B 0.2 (0.1, 0.4) 0.2 (0.1, 0.4)  0 (-0.2, 0.2) 
OP - HRG - WF02A 0.3 (0.0, 0.7) 0.3 (0.0, 0.7)  0 (-0.5, 0.5) 
 IP - HRG - PA34A 1.5 (0.4, 3.0) 1.4 (0.2, 3.0) 0.1 (-1.8, 2.1) 
 IP - HRG - PA34B 0.5 (0.0, 1.0) 0.2 (0.0, 0.4) 0.3 (-0.3, 1.0) 
 IP - HRG - PA34C 0.1 (0.0, 0.2) 0.4 (0.0, 0.9)  -0.3 (-0.8, 0.1) 
 IP - HRG - PA34D 0.3 (0.0, 0.6) 0.2 (0.0, 0.5) 0.1 (-0.3, 0.4) 
Item of resource use 
Adalimumab  
mean £ (95%CR) 
Placebo 
mean £ (95%CR) 
Difference in means 
(95% CR) 
Adalimumab 10340 (9392, 11245)  1761 (722, 2951)   8579 (7065, 9978)  
Methotrexate 778 (638, 910)  637 (462, 816)   141 (-80, 364)  
Concomitant medications  540 (379, 743)  249 (92, 471)  291 (11, 549) 
In-patient HRGs  2522 (1195, 4135)  2549 (1166, 4267)  -27 (-2198, 2158)  
Out-patient HRGs  700 (434, 1011)  692 (294, 1191)   8 (-559, 510)  
GP visits  91 (64, 122)  48 (23, 79)   43 (2, 84)  
Optician 21 (8, 37)  0  21 (8, 37)  
Nurse visits 18 (9, 27)  7 (0, 18)   11 (-3, 23)  
Physiotherapist 12 (4, 21) 9 (0, 20)  3 (-10, 15)  
Psychologist 3 (0, 6)  6 (1, 14)  -3 (-12, 4)  
Total cost  15980 (14213, 17943) 6248 (3922, 8889)   9732 (6562, 12793)  
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Table 4. Characteristics of patients included in the Bristol cohort16. 
Age at diagnosis  
Mean (SD) [range] 7.9 (3.8) [1-15] 
Sex N(%) 
Male 60 (38.2) 
Ethnicity N(%) 
Caucasian 122 (78.2) 
Asian 6 (3.9) 
African 1 (0.6) 
Other 6 (3.9) 
Unknown 22 (14.1) 
Aetiology N(%) 
JIA 91 (58.3) 
Idiopathic 66 (42.3) 
Type of uveitis 
Anterior 120 
Intermediate 28 
Panuveitis 8 
Posterior 1 
Year of diagnosis N(%) 
1997-2000 10 (6.4) 
2001-2005 37 (23.6) 
2005-2010 61 (38.9) 
2011-2015 48 (30.6) 
Biologics received N(%) (abatacept, adalimumab, etanercept, infliximab, tocilizumab) 
None 104 (66.2) 
One 41 (26.1) 
Two 9 (5.7) 
Three 2 (1.3) 
Five 1 (0.6) 
Adalimumab 47 (30.0) 
LogMAR > 0.3 at diagnosis N(%)* 
Best eye 12 (9.5) 
Worst eye 47 (37.3) 
Surgical procedures N ** 
Capsulotomy 3 
Cataract 15 
Glaucoma tube 1 
Iridectomy 2 
Trabeculotomy 10 
Vitrectomy 6 
* LogMAR data at diagnosis were available for 126 patients  
**A total of 37 procedures out of 268 observations 
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Table 5. Sensitivity analysis results 
 Costs QALYs ICER 
Univariate sensitivity analysis ADA + 
MTX  
MTX Incre-
mental 
ADA + 
MTX  
MTX Incre-
mental 
 
Base-case* £70,719 £31,403 £39,316 8.60 8.29 0.30 £129,025 
(i) Proportion administered adalimumab beyond 18-months        
Reduced to 0.23, reflecting the observed value £51,304 £31,403 £19,900 8.44 8.29 0.15 £131,511 
(ii) Duration of adalimumab treatment        
Adalimumab treatment for 18-months only £45,504 £31,403 £14,101 8.40 8.29 0.11 £133,656 
Adalimumab treatment for 18-months + 10 years £120,262 £31,403 £88,858 8.99 8.29 0.70 £127,646 
(iii) Adherence to treatment        
Adalimumab adherence based on vials issued (111%) £74,011 £31,175 £42,835 8.60 8.29 0.30 £140,576 
Adalimumab adherence based on accountability logs (94%) £68,800 £31,536 £37,264 8.60 8.29 0.30 £122,291 
Adherence based on patient diaries: Adalimumab (83%), 
MTX (adalimumab group) (61%), MTX (placebo group) (50%) 
£59,896 £24,638 £36,258 8.60 8.29 0.30 £115,708 
(iv) Time horizon of analysis        
18-months £16,336 £1,962 £14,374 1.36 1.25 0.11 £136,751 
(v) Price of adalimumab        
25% reduction in the price of adalimumab  £56,665 £27,821 £28,844 8.60 8.29 0.30 £94,661 
50% reduction in the price of adalimumab £48,865 £28,361 £20,504 8.60 8.29 0.30 £67,288 
(vi) Visual impairment rates        
Adalimumab:Placebo VI proportions High:Low £70,864 £31,147 £39,716 8.60 8.29 0.30 £130,586 
Adalimumab:Placebo VI proportions Low:High £70,574 £31,659 £38,915 8.60 8.29 0.31 £127,471 
All placebo-group participants transition to VI state £70,719 £45,224 £25,495 8.60 8.27 0.32 £78,524 
All adalimumab patients transition to no VI and all placebo 
patients transition to VI and remain in those states 
£68,722 £50,902 £17,820 8.60 8.26 0.34 £53,072 
(vii) Discount rate        
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No discounting  £77,634 £36,743 £40,621 9.88 9.57 0.32 £128,886 
        
Two-way sensitivity analyses 
 
Incremental cost-effectiveness ratio (per QALY gained) 
Cost of adalimumab (% of base-case) 100% 75% 50% 25% 
(i) Disutility in VI (% of base-case)     
Base-case disutility* £129,025 £94,661 £67,288 £39,916 
200% £128,860 £94,540 £67,202 £39,864 
300% £128,695 £94,419 £67,116 £39,813 
400% £128,531 £94,298 £67,030 £39,763 
500% £128,367 £94,178 £66,945 £39,712 
(ii) Progression of adalimumab patients to VI (% of base-case)     
Base-case progression* £129,025 £94,661 £67,288 £39,916 
10% £128,366 £94,029 £66,678 £39,327 
25% £127,362 £93,067 £65,749 £38,431 
50% £125,645 £91,422 £64,161 £36,900 
75% £123,874 £89,724 £62,521 £35,319 
100% £122,044 £87,970 £60,829 £33,687 
*In the base-case analysis, with a 18-month plus 10 year time horizon, all patients in the adalimumab group received treatment according to protocol (full 
adherence) for a total of 18-months plus 3 years (54 months).  ADA – adalimumab; MTX – methotrexate; VI – visual impairment 
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Figure 1: Model structure 
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Figure 2: Cost-effectiveness plane 
 
